2026 ANNUAL REPORTRHYTHM BIOSCIENCES LIMITED (ASX:RHY)ACN 619 459 335RHYTHM’S ColoSTAT® IS A SIMPLE BLOOD TEST THAT DETECTS THE PROTEIN BIOMARKERS IN THE BLOOD, THAT ARE INDICATIVE OF THE PRESENCE OF COLORECTAL CANCER.2CONTENTS4 Key Milestones6 Company Overview 10 Non-Executive Interim Chair's...
FY26 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- AGM date and closing date for director nominations
- Board Changes
- Initial ColoSTAT Assessment in UK opens new market access
- Initial Director's Interest Notice - Carl Stubbings
- Initial Director's Interest Notice - Maureen Baker
Later from Rhythm Biosciences
- FY26 Appendix 4G and Corporate Governance Statement
- Final Director's Interest Notice - Gavin Fox-Smith
- ColoSTAT Economic Study - Australian Public Health Savings
- Notice of Annual General Meeting/Proxy Form
- Quarterly Activities Report and Appendix 4C
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences